Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Curve is considering removing TUSD as collateral for crvUSD due to concerns raised by SEC allegations

Curve is considering removing TUSD as collateral for crvUSD due to concerns raised by SEC allegations

Bitget2024/09/25 23:48

Curve Finance is considering removing TrueUSD (TUSD) as collateral for its stablecoin crvUSD, due to the U.S. Securities and Exchange Commission (SEC) bringing securities law violation charges against TrueCoin and TrustToken. The charge alleges that 99% of TUSD's reserve funds are invested in high-risk offshore funds, raising concerns about its safety and solvency. A proposal has been put forward in Curve's governance forum suggesting reducing the TUSD collateral limit for crvUSD to zero, and decreasing association with PayPal's stablecoin PYUSD to mitigate related risks. Currently, the main collaterals for crvUSD include Ethereum (ETH) and Wrapped Bitcoin (WBTC).

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well